Agenus Inc. — Q2 2012 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2012. Unaudited consolidated financial statements. Agenus is a biotechnology company developing cancer and infectious-disease therapies, including QS-21 adjuvant, Prophage vaccines and HerpV.
Key financial results
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Total revenue | $0.627 million | $0.786 million | $14.002 million | $1.458 million |
| Operating income (loss) | ($5.771 million) | ($4.702 million) | $2.029 million | ($9.724 million) |
| Net loss | ($6.923 million) | ($5.758 million) | ($0.155 million) | ($11.721 million) |
| Net loss attributable to common stockholders | ($7.121 million) | ($5.955 million) | ($0.551 million) | ($12.117 million) |
| Basic and diluted loss per share | ($0.31) | ($0.31) | ($0.02) | ($0.64) |
- Six-month revenue included substantial nonrecurring license payments: $6.5 million recognized under an expanded GSK license and $6.25 million from an amended license of non-core technologies. The filing states 2012 revenue primarily reflected one-time payments and is not indicative of future results.
- Research and development expense was $2.9 million for Q2, up 3%, and $5.6 million for the first half, broadly unchanged year over year. General and administrative expense rose 26% in Q2 to $3.4 million and 13% in the first half to $6.2 million, with higher share-based compensation a major factor.
- Net interest expense was $1.2 million for Q2 and $2.3 million for the first half, up from the comparable periods, primarily due to increased principal on the 8% senior secured convertible notes and interest paid through additional notes.
- Cash and cash equivalents were $25.5 million at June 30, up $14.7 million from year-end. Six-month operating cash flow was positive $7.9 million versus cash used of $8.7 million in 2011; the improvement largely reflected license-related one-time payments. Investing cash use was $0.1 million and financing cash provided was $6.8 million.
- Current assets were $26.5 million and current liabilities $4.6 million. Total assets were $33.3 million; stockholders’ deficit was $11.4 million. No operating margin is stated; the company reported operating losses in Q2.
- Debt principal was approximately $39.4 million, including $39.0 million of 8% senior secured convertible notes due August 2014 and $0.1 million of 5.25% convertible senior notes due 2025. The notes’ carrying amounts differ from principal.
Material changes, outlook and risks
- In March, Agenus received a nonrefundable $9.0 million payment from GSK for a first right to negotiate and expanded license rights; $2.5 million was creditable against future manufacturing technology-transfer royalty payments. It also received $6.25 million for an exclusive license amendment that bought out a royalty stream. The GSK first right to negotiate lasts five years.
- Equity sales under ATM programs generated approximately $7.2 million net proceeds in the first half. From July 1 through August 8, the company received a further $2.8 million net. Common shares issued rose to 23.9 million at June 30 from 21.5 million at year-end.
- Management estimated 2012 net cash burn of $13–16 million and expected existing resources, post-quarter ATM proceeds and estimated license, supply and collaboration proceeds to fund requirements through Q4 2013. This outlook depends on assumptions and does not assure funding beyond that period; management expects to seek additional capital and may reduce or discontinue activities.
- Clinical and commercial prospects remain uncertain. Agenus planned to start a Phase 2 HerpV trial in the second half of 2012; Phase 2 studies of Prophage G-100 and G-200 were underway. The company anticipated first QS-21-containing product launches around 2014, but these depend on licensees’ trials, regulatory approvals and commercialization. Oncophage was approved only in Russia for a limited kidney-cancer indication, with minimal sales to date.
- Key risks include continued operating losses and possible inability to raise capital; significant debt and restrictive note covenants, with QS-21 and HerpV subsidiary equity pledged as security; clinical, regulatory, manufacturing and reimbursement uncertainty; reliance on partners and licensees; competition and intellectual-property exposure. The QS-21 composition-of-matter patent had expired in virtually all territories.
- Management reported disclosure controls were effective and no material change in internal control over financial reporting during the six-month period. The company reported no material pending legal proceedings beyond ordinary-course matters.
Investor facts to verify
- How much of the reported first-half revenue and positive operating cash flow was one-time license-related, and whether recurring royalties or other receipts can replace it.
- Whether the stated runway through Q4 2013 remains supportable against actual cash burn, planned trials and additional funding needs.
- Terms, covenants, collateral and repayment or conversion outcomes for the $39.0 million 2006 Notes due in August 2014.
- Progress and outcomes for the planned HerpV Phase 2 study, ongoing Prophage trials, and licensees’ QS-21 programs, including the basis for anticipated 2014 launches.
- Potential dilution from ATM sales, outstanding equity awards and any additional capital raising.